BRIEF-RepliCel forms strategic plan for 2017-2019 focused on maturing assets
May 25, 2017 at 06:20 AM EDT
* RepliCel Life Sciences Inc - RepliCel continues to make significant progress on its nearest-term commercial asset, dermal injector (RCI-02)